Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 ...(operations through 2010 based on current...),Health

Preclinical / Research

-- Publication of data supporting Sangamo's first ZFN Therapeutic program for the treatment of HIV/AIDS in high-impact journal Nature Biotechnology demonstrating highly efficient and specific ZFN-modification of CCR5 in human T-cells resulting in an increase in CD4 T-cell counts and a reduction in viral load in an animal model of HIV infection (Perez et al., 2008, Nat Biotechnol.,26: 808).

-- Nature Biotechnology publication establishing the utility of ZFNs in the generation of transgenic animals and the potential broadening of the production of knockout transgenic models beyond mouse models (Doyon et al., 2008, Nat. Biotechnol. 26: 702).

-- Publication of data in the journal Proceedings of the National Academy of Sciences (PNAS) establishing Sangamo's ZFN technology as a new approach for rapid generation of "knock-out" cell lines (Santiago et al., 2008, PNAS 105: 5809).

Select 2009 Objectives

During the briefing Sangamo will also discuss the following objectives for 2009:

-- Sangamo expects to file an IND for SB-313 to evaluate the drug in a Phase 1 trial in subjects with glioblastoma.

-- The company expects to present data from its three ongoing Phase 2 clinical trials of SB-509 in subjects with DN, SB-509-601 in subjects with mild to moderate DN, SB-509-701 subjects with moderate to severe DN with a blocked nerve and SB-509-703 in stem cell mobilization.

-- Establishment of a strategic partnership for SB-509.

-- Sangamo estimates that it expects to end 2009 with approximately $40M in cash and cash equivalents, based on current expense projections and expected progress in existing corporate relationships.

The presentation from today's Investor and Analyst Briefing will be archived on Sangamo's website and is a
'/>"/>